Broad access and affordability solutions help you get your patients started on IZERVAY
We know access matters
This is why IZERVAY My Way was built by retina for retina to help streamline access, affordability, and reimbursement support that you can count on
91% of patients
covered by any Medicare plan can start IZERVAY as their first branded GA treatment5*
*Coverage for IZERVAY may be subject to prior authorization requirements. Percentage listed herein includes Medicare Part B and Medicare Advantage covered lives where IZERVAY is covered (unrestricted) or covered subject to prior authorization, without a step edit in place. Based on Managed Markets Insight & Technology data, June 2025.
Enroll your patients today
IZERVAY My Way can help with benefits investigations (BI) and the patient enrollment process
Enroll on the IZERVAY My Way portal
Enroll patients online, upload documents, and check patient enrollment all in one place
Download the IZERVAY My Way enrollment form and submit it via email or fax
Email:
Support@IZERVAYMyWay.com
Fax:
1-833-C5MYWAY (1-833-256-9929)
Download resources
Streamline access and support with resources built for you
Billing and coding
Access, coverage, and affordability support
ECP sample letters
Patient materials
See IZERVAY My Way offerings
IZERVAY My Way offers flexible options and dedicated experts for:
Getting Started
- Portal enrollment
- Benefits investigation
Access
- Prior authorization (PA) information and assistance†
- PA appeals and denials information and assistance†
- Benefits reverification
Affordability
- IZERVAY Commercial Copay Program‡
- Patient Assistance Program§
Reimbursement
- Billing and coding||
- Claims appeals information and assistance†
Affordability
IZERVAY My Way offers potential affordability options for your patients across insurance types
Commercial
IZERVAY Commercial Copay Program
- Eligible commercial patients may pay as little as $0 copay for IZERVAY, subject to an assistance limit of up to $20,000 per calendar year‡
- Eligible patients may pay as little as $0 copay for IZERVAY administrations, subject to an assistance limit of up to $1,500 per calendar year‡
- Click here to view full IZERVAY Commercial Copay Program Terms and Conditions
Underinsured/uninsured
Patient Assistance Program
- Eligible underinsured/uninsured patients may be able to receive IZERVAY at no cost§
- Patients must meet program eligibility requirements, including financial criteria
- Click here to view full Astellas Patient Assistance Program Terms and Conditions
†The healthcare provider remains responsible for populating all clinical content.
‡Eligibility criteria and terms and conditions apply. Patients are not eligible for the program if they are self-paying or if the patient is enrolled in a state or federal healthcare program. There is a maximum benefit limit of $20,000 for product cost share per calendar year and $1,500 for the administration cost share reimbursement to the patient. If the patient’s total out-of-pocket bill exceeds the cap established by Astellas, the patient will be responsible for the additional balance. Patients residing in Massachusetts and patients receiving IZERVAY treatment in Massachusetts may be eligible for copay assistance for the cost of IZERVAY only, and are not eligible for copay assistance for the administration of IZERVAY. Offer is not health insurance and is void where prohibited by law. Astellas reserves the right to revoke, rescind, or amend this offer without notice for any reason. For full terms and conditions, visit IZERVAYecp.com/PatientSupport.
§Eligibility criteria and terms and conditions apply. For full terms and conditions, visit IZERVAYecp.com/PatientSupport.
||The responsibility to determine coverage, reimbursement, and appropriate coding for a patient remains at all times with the provider. Information provided by IZERVAY My Way should in no way be considered a guarantee of coverage or reimbursement for any product or service.
Learn how to get started with support from a dedicated IZERVAY My WAY Access Coordinator
Visit IZERVAY My WayFind a practice
Next pageIMPORTANT SAFETY INFORMATION AND INDICATION
CONTRAINDICATIONS
IZERVAY® is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.
WARNINGS AND PRECAUTIONS
Endophthalmitis and Retinal Detachments
- Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
Neovascular AMD
- In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.
Increase in Intraocular Pressure
- Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.
ADVERSE REACTIONS
Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.
INDICATION
IZERVAY (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Please see full Prescribing Information for more information.
To request medical information, please call 1-800-727-7003 or send an email to medinfo.americas@astellas.com. To report an adverse event or product complaint, please call 1-800-727-7003 or send an email to safety-us@astellas.com.
IMPORTANT SAFETY INFORMATION AND INDICATION
CONTRAINDICATIONS
IZERVAY® is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.
WARNINGS AND PRECAUTIONS
Endophthalmitis and Retinal Detachments
- Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
Neovascular AMD
- In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.
Increase in Intraocular Pressure
- Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.
ADVERSE REACTIONS
Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.
INDICATION
IZERVAY (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Please see full Prescribing Information for more information.
To request medical information, please call 1-800-727-7003 or send an email to medinfo.americas@astellas.com. To report an adverse event or product complaint, please call 1-800-727-7003 or send an email to safety-us@astellas.com.